Mr. Ghosh has 30+ years of product development and business experience in the medical devices, electronics and other high-technology industries. He serves as the CEO of Hepatiq, Inc.

Mr. Ghosh is also Chief Engineer and President of Syprosoft, Inc., which he founded in 2002. At Syprosoft he helped develop a wide variety of products, including a stroke therapy system, a circulatory assistance device, a vital signs monitor, a surgical laser, a pulse oximeter, a blood collection system, an automatic defibrillator, a hematology image processor, and a 3D confocal imaging system. He has helped obtain FDA clearance for many of these products.

Previously, Mr. Ghosh has held VP and Director level positions at several leading technology companies. At Trimedyne, he headed the development of lasers for use in minimally invasive surgeries. At Image Analysis, he led the development of a new bone densitometer and successfully sold this system to both Philips Medical Systems and GE Medical Systems. At Magnaflux, he headed the development of computerized test equipment for automotive and aerospace applications. At Nucletron he helped develop a radiation therapy simulator. He started his career with GE Medical Systems, where he was a key designer for GE’s first leading CT scanner. Mr. Ghosh also teaches courses at UCI and UCLA Extensions through his educational services firm VidyaConnect.

Mr. Ghosh invented the algorithms for automating the QLSS techniques so it can be easily used by any operator. He is skilled in creating image processing algorithms, and in the use of tools, such as, Matlab, C++ and DICOM. He has successfully developed software for: CT image reconstruction, bone densitometry, cell counting, X-ray imaging, radiation therapy simulation, pupil tracking, surgical image and video processing, and face recognition. He has helped develop, obtain regulatory clearance for and commercialize many products.

Mr. Ghosh has an M.S. in Electrical Engineering from the University of Rochester, and an M.B.A. from Marquette University.

Dr. Hoefs has 30+ years of clinical and research experience with liver disease. He serves as the COO of Hepatiq, Inc.

Dr. Hoefs pioneered the development of the quantitative liver spleen scan (QLSS) and has published multiple papers supporting its utility. He developed unique solutions to practical problems with the application of QLSS. For example, the normal range was wide initially. Feeding prior to the scan and consuming a can of Ensure around the time of the scan narrowed the normal range, allowing better distinction of normals from those with chronic liver disease (CLD). He tested the technique against disease severity at peritonoscopy and with the explanted liver showing a strong correlation with severity.

Dr. Hoefs is an expert in the clinical implications of the QLSS results. He has processed scans clinically for over 20 years and has encountered virtually every problem imaginable. This invaluable experience has helped improve and perfect the automated HEPATIQ image analysis. Furthermore, he applies this knowledge to train physicians at the customer sites to implement HEPATIQ clinically.

Dr. Hoefs has an extensive academic background in liver disease and has published articles in several of the most prestigious journals in his field, including Gastroenterology, Hepatology and the New England Journal of Medicine. He published data that led to the development of the serum-ascites albumin gradient (SAAG) which is used worldwide to initiate the evaluation of ascites. He has the credentials to influence the field and promote the HEPATIQ technology to the medical community.

Dr. Hoefs is a recognized authority on liver disease assessment and management. He understands clinical liver disease and developed the QLSS methods to measure hepatic function, fibrosis, hepatic and spleen volume and cirrhosis. He has been involved in multiple studies documenting the clinical value of the QLSS techniques in patients with CLD. Over the past 20 years at UCIMC, Dr. Hoefs has initiated the development of three computer programs to extract information on specific scanners from the 99Tc sulfur colloid liver-spleen SPECT and planar scans. He has collected data and experience on over 20,000 patients with chronic liver disease. He has published extensively